Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma × elotuzumab × Plasma cell × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1 Lymphoid 1

Conditions

Multiple Myeloma 51 Recurrence 9 Neoplasms, Plasma Cell 3 Smoldering Multiple Myeloma 2 Neoplasms 1 Lymphoma 1 Leukemia, Plasma Cell 1 Leukemia, Myeloid, Acute 1 Immunoglobulin Light-chain Amyloidosis 1

Interventions

Cyclophosphamide 63 fludarabine phosphate 52 Busulfan 39 Peripheral Blood Stem Cell Transplantation 34 Tacrolimus 33 Mycophenolic Acid 31 Filgrastim 31 Antilymphocyte Serum 30 Radiotherapy 28 fludarabine 27 Melphalan 27 Whole-Body Irradiation 26 Cyclosporine 26 Methotrexate 19 Etoposide 19 Cord Blood Stem Cell Transplantation 16 Rituximab 14 Methylprednisolone 14 Biopsy 14 Specimen Handling 11 Stem Cell Transplantation 10 Magnetic Resonance Spectroscopy 10 Cytarabine 10 Sirolimus 9 Dexamethasone 9 Alemtuzumab 9 Prednisone 8 Granulocyte Colony-Stimulating Factor 8 thymoglobulin 7 Epoetin Alfa 7

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01239797 2022-06-01

ELOQUENT - 2

Bristol-Myers Squibb

Phase 3 Completed

646 enrolled 16 charts

LymphoidPlasma cell

Lymphoma, Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡